Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age
2015; Oxford University Press; Volume: 61; Issue: suppl_5 Linguagem: Inglês
10.1093/cid/civ672
ISSN1537-6591
AutoresMilagritos D. Tapia, Helen Findlow, Olubukola T. Idoko, Marie‐Pierre Préziosi, Prasad S. Kulkarni, Godwin Enwere, Cheryl M. Elie, Varsha Parulekar, Samba O. Sow, Fadima Cheick Haidara, Fatoumata Diallo, Moussa Doumbia, Adebayo Akinsola, Richard A. Adegbola, Beate Kampmann, Julie Chaumont, Lionel Martellet, Elisa Marchetti, Simonetta Viviani, Yuxiao Tang, Brian D. Plikaytis, F. Marc LaForce, George M. Carlone, Ray Borrow,
Tópico(s)Virology and Viral Diseases
ResumoBackground. Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated.
Referência(s)